托法替尼与生物制剂治疗溃疡性结肠炎患者结肠切除术不良事件率比较:多中心观察性研究
结果显示托法替尼与生物制剂的术后安全性相当,未发现药物类别与早期或晚期并发症风险升高相关。急诊手术和高剂量激素增加早期并发症风险,腹腔镜手术降低部分风险。
要点
- 托法替尼术前暴露的术后并发症风险与生物制剂相当。
- 急诊手术和高剂量激素增加早期并发症及再手术风险。
- 腹腔镜手术降低早期并发症、感染及晚期再入院风险。
核心结论
- 术前托法替尼治疗在溃疡性结肠炎结肠切除术患者中表现出与生物制剂相当的术后安全性。
主要发现
- 除抗TNF-α药物早期静脉血栓栓塞事件率较高(P=0.047)和维得利珠单抗晚期静脉血栓栓塞事件率较高(P=0.03)外,其他结局均无显著差异。
- 多变量分析中,药物类别与早期和晚期并发症风险升高无关。
- 急诊结肠切除术增加早期并发症(OR 1.92,95%CI 1.06-3.48)、早期再入院(OR 4.79,95%CI 1.12-20.58)和早期再手术(OR 7.49,95%CI 1.17-47.85)风险。
- 高剂量激素增加早期并发症(OR 1.96,95%CI 1.08-3.57)、早期手术部位并发症(OR 2.03,95%CI 1.01-4.09)和早期再手术(OR 7.52,95%CI 1.42-39.82)风险。
关键数值与推荐
- 主要结局为术后30天(早期)和90天(晚期)内任何并发症的发生。
- 次要结局包括感染、脓毒症、手术部位并发症、静脉血栓栓塞事件、再入院和再手术。
临床怎么用
- 对于需要结肠切除术的溃疡性结肠炎患者,术前使用托法替尼并非术后并发症的额外风险因素,可与生物制剂同等考虑。
- 应尽量避免急诊手术和高剂量激素暴露,以降低术后早期并发症风险。
- 在条件允许时,优先选择腹腔镜手术以减少早期并发症和再入院。
局限性
- 回顾性观察性设计可能存在选择偏倚和混杂因素。
- 样本量有限,各药物组例数不均,可能影响统计效能。
- 未报告长期结局及具体用药剂量和疗程细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the risk of postoperative complications of tofacitinib exposure before colectomy in comparison with biologics. METHODS: A multicenter, retrospective, observational study was conducted in patients with UC who underwent total colectomy for medically refractory disease, exposed to tofacitinib or a biologic before surgery. Primary outcome was the occurrence of any complication within 30 (early) and 90 (late) days after surgery. Secondary outcomes were the occurrence of infections, sepsis, surgical site complications, venous thromboembolic events (VTE), hospital readmissions, and redo surgery within the same timepoints. RESULTS: Three hundred one patients (64 tofacitinib, 162 anti-tumor necrosis factor-α agents, 54 vedolizumab, and 21 ustekinumab) were included. No significant differences were reported in any outcome, except for a higher rate of early VTE with anti-tumor necrosis factor-α agents ( P = 0.047) and of late VTE with vedolizumab ( P = 0.03). In the multivariate analysis, drug class was not associated with a higher risk of any early and late complications. Urgent colectomy increased the risk of any early (odds ratio [OR] 1.92, 95% confidence interval [CI] 1.06-3.48) complications, early hospital readmission (OR 4.79, 95% CI 1.12-20.58), and early redo surgery (OR 7.49, 95% CI 1.17-47.85). A high steroid dose increased the risk of any early complications (OR 1.96, 95% CI 1.08-3.57), early surgical site complications (OR 2.03, 95% CI 1.01-4.09), and early redo surgery (OR 7.52, 95% CI 1.42-39.82). Laparoscopic surgery decreased the risk of any early complications (OR 0.54, 95% CI 0.29-1.00), early infections (OR 0.39, 95% CI 0.18-0.85), and late hospital readmissions (OR 0.34, 95% CI 0.12-1.00). DISCUSSION: Preoperative tofacitinib treatment demonstrated a postoperative safety profile comparable with biologics in patients with UC undergoing colectomy.
引用
- Dragoni G, Innocenti T, Amiot A, et al. Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study. Am J Gastroenterol. 2024. PMID: 38305302. doi:10.14309/ajg.0000000000002676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。